New Alzheimer's Drugs in 2025: What They Cost and Who Qualifies
A new generation of Alzheimer's treatments has moved from research headlines to real prescriptions — and families are understandably asking hard questions. What do these drugs actually do? Who can get them? And what will it cost? Here's a clear-eyed look at where things stand.
What's Actually New: Disease-Modifying Treatments
For decades, Alzheimer's drugs only managed symptoms — helping with memory or behavior for a limited time but doing nothing to slow the disease itself. That changed with the arrival of a new class called amyloid-targeting therapies, also called anti-amyloid monoclonal antibodies.
These drugs work by targeting and clearing amyloid plaques — abnormal protein deposits in the brain that are a hallmark of Alzheimer's disease. The goal is to slow cognitive decline, not reverse it. That distinction matters enormously when setting expectations.
The two drugs in this class that have received full FDA approval (not just accelerated approval) as of 2025 are lecanemab (brand name Leqembi) and donanemab (brand name Kisunla). Both are administered by intravenous (IV) infusion at a clinical facility, not as a daily pill.
Who Qualifies — and It's a Narrow Window 🔬
These treatments are not for everyone with Alzheimer's or memory concerns. Current approvals are specifically for adults with early-stage Alzheimer's disease — meaning:
- Mild cognitive impairment (MCI) due to Alzheimer's, or
- Mild Alzheimer's dementia
People with moderate or advanced Alzheimer's are not candidates under current approvals. The drugs are designed to slow decline at a stage where meaningful cognitive function is still present — they cannot restore what's already been lost.
Key Eligibility Factors
Beyond disease stage, qualifying involves several layers of evaluation:
| Factor | What It Involves |
|---|---|
| Confirmed amyloid pathology | A PET scan or cerebrospinal fluid (CSF) test to verify amyloid plaques are present |
| Genetic screening | Testing for the APOE ε4 gene variant, which increases risk of a serious side effect |
| Brain imaging baseline | MRI to check for existing bleeding or swelling |
| Overall health profile | Certain heart conditions, blood thinners, and other health factors may affect eligibility |
| Specialist evaluation | Typically requires assessment by a neurologist or memory specialist |
The genetic factor deserves attention: people who carry two copies of the APOE ε4 gene (called homozygous APOE ε4) face a significantly higher risk of a side effect called ARIA (amyloid-related imaging abnormalities) — brain swelling or microbleeds detectable on MRI. Some prescribing guidelines recommend against treatment for this group, while others allow it with intensive monitoring. This is an active area of clinical discussion.
What These Drugs Cost — and Why It's Complicated 💰
The list prices for these drugs run into tens of thousands of dollars per year per patient — figures that have been widely reported and are in the range of roughly $26,000 to $32,000 annually at list price, depending on the drug and dosing schedule. However, list price is rarely what anyone actually pays, and the real cost depends heavily on insurance coverage.
Medicare Coverage
Medicare coverage for these drugs has been one of the most-watched policy developments in recent years. After an initial restrictive coverage determination, Medicare now covers FDA-approved anti-amyloid therapies for beneficiaries who meet clinical criteria — but with conditions.
Coverage typically requires:
- Enrollment in a qualifying registry or evidence generation program (this was a requirement tied to Medicare's coverage with evidence development policy, though terms continue to evolve)
- Treatment at a facility participating in approved data collection
- Meeting the clinical eligibility criteria above
The Medicare Part D drug benefit redesign taking effect in 2025 — which caps out-of-pocket costs for Part D enrollees — may significantly affect what Medicare beneficiaries pay for high-cost drugs. The specifics depend on a person's Part D plan structure and whether the drug falls under Part B (infusion drugs administered in a clinical setting) or Part D.
Important: Infused drugs like these are often covered under Medicare Part B rather than Part D, which has different cost-sharing rules. Understanding which part applies matters for calculating out-of-pocket exposure.
Private Insurance and Medicare Advantage
Coverage through private insurance and Medicare Advantage plans varies considerably. Some plans cover these treatments with prior authorization; others have not yet established coverage policies or impose additional criteria. The prior authorization process for these drugs can be intensive and may require documented specialist evaluations and imaging results.
What Families Should Know About Costs
Even with insurance, costs can be significant when you factor in:
- Diagnostic testing (amyloid PET scans can cost thousands of dollars; coverage varies)
- Infusion facility fees
- Ongoing MRI monitoring (required every few months during treatment)
- Specialist visits
Patient assistance programs from manufacturers exist and can help reduce costs for those who qualify based on income or insurance status — but eligibility and benefit amounts vary.
Where Access Remains a Real Challenge
Even for people who clearly qualify medically, access is not automatic. Several practical barriers affect who actually receives these treatments:
- Geographic availability: Infusion centers and specialists experienced with these drugs are concentrated in urban and academic medical centers. Rural access remains limited.
- Diagnostic infrastructure: Amyloid PET scans are not universally available, and there's a shortage of trained interpreters.
- Time-sensitive window: Because these drugs only work early, delays in diagnosis — which remain common — can mean someone has progressed past the eligible stage before treatment is even considered.
- Caregiver and logistical demands: Regular infusion appointments and monitoring MRIs place real demands on patients and families.
What to Evaluate If This Is Relevant to Your Situation 🧠
If you or a family member has received an early Alzheimer's diagnosis, the questions worth exploring with a neurologist or memory specialist include:
- Has the diagnosis been confirmed with amyloid testing? A clinical diagnosis alone isn't sufficient for these treatments.
- What stage is the disease currently? Timing matters more here than with almost any other treatment decision.
- What is your APOE status, and how does it affect risk-benefit considerations?
- What does your specific insurance cover, and what will the out-of-pocket cost realistically be?
- Is there a qualified infusion center and monitoring program accessible to you?
These aren't questions with universal answers — they depend on a person's medical history, genetic profile, insurance, geography, and values around risk tolerance. A neurologist who specializes in memory disorders is the right starting point for anyone seriously evaluating these options.
The Bigger Picture
These drugs represent a genuine scientific milestone — the first treatments shown to meaningfully slow Alzheimer's progression in clinical trials. But "meaningful slowing" in trial data doesn't translate to the same experience for every patient, and the risks, logistics, and costs are real. The landscape is also still evolving: coverage policies, prescribing guidelines, and the evidence base will all continue to develop.
Knowing what questions to ask, and knowing that the answers depend on your specific situation, is where useful preparation starts.
